Previous 10 | Next 10 |
Here is another quality price-gain healthcare stock Making heart pumps since 1981, Abiomed Inc. ( ABMD ) has helped heart failure victims in North America, Europe, and Japan recover life regularly. See what their stock may do for your portfolio’s palpitations at this opportune point...
Impella is the most studied heart pump; Subject of comprehensive post-market surveillance, 550+ academic publications, and a landmark randomized controlled trial In a milestone for scientific research, Abiomed (NASDAQ: ABMD) has now invested more than $100 million over the past five...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 63 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wayfair Inc. (NYSE:W), MSCI Inc (NYSE:MSCI), ABIOMED, Inc. (NASDAQ:ABM...
In a note, Jefferies' Raj Denhoy (Buy/$460) says yesterday's 6% selloff in Abiomed (NASDAQ: ABMD ) in reaction to a potential higher mortality rate in patients receiving the Impella RP heart pump in a post-market study is no big thing, adding that there may be a "minor hiccup" ...
Abiomed, Inc. (ABMD) Q3 2019 Results Conference Call January 31, 2019 08:00 AM ET Company Participants Mike Minogue - Chairman, President and CEO Todd Trapp - VP and CFO Conference Call Participants Chris Pasquale - Guggenheim Jayson Bedford - Raymond James Bruce Nudell ...
The following slide deck was published by ABIOMED, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Abiomed ( ABMD ) Q3 results : Revenues: $200.6M (+30.3%). More news on: ABIOMED, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Cloud-based monitoring platform gains CE Mark, adding to FDA PMA approval Abiomed (NASDAQ:ABMD) has achieved CE Mark for Impella Connect, the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing of the Impella console for physicians and hospital st...
Abiomed (NASDAQ: ABMD ): Q3 GAAP EPS of $0.97 beats by $0.03 . More news on: ABIOMED, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...